Clinical Decision Support in Non-typhoidal Salmonella Bloodstream

Status Completed

Clinical Trial Summary

In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are a frequent cause of bloodstream infection, display high levels of antibiotic resistance and have a high case fatality rate (15%). In Kisantu hospital in the Democratic Republic of Congo (DR Congo), NTS account for 75% of bloodstream infection in children and many children are co-infected with Plasmodium falciparum (Pf) malaria. NTS bloodstream infection presents as a non-specific severe febrile illness, which challenges early diagnosis and, as a consequence, prompt and appropriate antibiotic treatment.Moreover, at the first level of care, frontline health workers have limited expertise and diagnostic skills and, as a consequence, clinical danger signs that indicate serious bacterial infections are often overlooked. Basic handheld diagnostic instruments and point-of-care tests can help to reliably detect danger signs and improve triage, referral and the start of antibiotics, but there is need for field implementation and adoption to low-resource settings. Further, it is known that some clinical signs and symptoms are frequent in NTS bloodstream infections. The integration of these clinical signs and symptoms in a clinical decision support model can facilitate the diagnosis of NTS bloodstream infections and target antibiotic treatment. The investigators aim to develop such a clinical decision support model based on data from children under five years old admitted to Kisantu district referral hospital in the Democratic republic of the Congo. While developing the model, the investigators will focus on the signs and symptoms that can differentiate NTS bloodstream infection from severe Pf malaria and on the clinical danger signs that can be assessed by handheld diagnostic instruments and point-of-care tests. The deliverable will be a clinical decision support model ready to integrate in an electronic decision support system.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04473768
Study type	Observational
Source	Institute of Tropical Medicine, Belgium
Contact
Status	Completed
Phase
Start date	February 1, 2021
Completion date	January 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04130282` - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine	Phase 1
Completed	`NCT04049916` - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission	Phase 2/Phase 3
Active, not recruiting	`NCT03814616` - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections	Phase 2
Active, not recruiting	`NCT04079621` - Short Course Radical Cure of P. Vivax Malaria in Nepal	Phase 4
Completed	`NCT05135273` - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali	Phase 1
Not yet recruiting	`NCT06083688` - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi	Phase 4
Recruiting	`NCT03511443` - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections	N/A
Completed	`NCT05550909` - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali	Phase 2
Recruiting	`NCT05306067` - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed	`NCT05081089` - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali	Phase 2
Recruiting	`NCT05150808` - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania	Phase 3
Recruiting	`NCT05757167` - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics	Phase 4
Completed	`NCT01992900` - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria	Phase 2
Completed	`NCT04565184` - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde	Phase 4
Completed	`NCT03896724` - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso	Phase 1/Phase 2
Completed	`NCT03454048` - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2	N/A
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Completed	`NCT03138096` - Safety and Protective Efficacy of Pb(PfCS@UIS4)	Phase 1/Phase 2
Recruiting	`NCT04271306` - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.	Phase 1
Recruiting	`NCT05058885` - Plasmodium Vivax Among Duffy Negative Population in Cameroon.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children — DeNTS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms